{"id":"etanautine","rwe":[{"pmid":"30000938","year":"2006","title":"Diphenhydramine.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"14352537","year":"1954","title":"[Modifications in the resistance to oxygen deficiency in the guinea pig after administration of etanautine].","finding":"","journal":"Comptes rendus des seances de la Societe de biologie et de ses filiales","studyType":"Clinical Study"}],"tags":[{"label":"etanautine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"N04AB01","category":"atc"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"nautamine","offLabel":[],"synonyms":["etanautine","bietanautine","nautamine"],"timeline":[],"approvals":[],"brandName":"Nautamine","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"etanautine","explanation":"Think of acetylcholine like a messenger in your brain that helps you move and respond to the world around you. When acetylcholine is broken down too quickly, it can be hard to move or think clearly. Etanautine helps by slowing down the breakdown of acetylcholine, so it can do its job more effectively.","oneSentence":"Etanautine works by blocking the action of acetylcholinesterase, an enzyme that breaks down the neurotransmitter acetylcholine.","technicalDetail":"Etanautine acts as a reversible inhibitor of acetylcholinesterase, the enzyme responsible for the hydrolysis of acetylcholine into choline and acetic acid."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Etanautine","title":"Etanautine","extract":"Etanautine, also known as diphenhydramine monoacefyllinate, is an anticholinergic used as an antiparkinsonian agent. It is a 1:1 salt of diphenhydramine with acefylline, similar to the diphenhydramine/8-chlorotheophylline combination product dimenhydrinate."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4534","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=etanautine","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Etanautine","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T11:05:29.804264","biosimilars":[],"competitors":[{"drugName":"orphenadrine","drugSlug":"orphenadrine","fdaApproval":"1957-05-10","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"etanautine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"orphenadrine","brandName":"orphenadrine","genericName":"orphenadrine","approvalYear":"1957","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"97H5S09M4T","UMLSCUI":"C3652696","ChEMBL_ID":"CHEMBL3707215","DRUGBANK_ID":"DB13636","PUBCHEM_CID":"10255142","SECONDARY_CAS_RN":"857401-00-4"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":2,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N04AB01","allCodes":["N04AB01"]},"biosimilarFilings":[],"recentPublications":[{"date":"2006","pmid":"30000938","title":"Diphenhydramine.","journal":""},{"date":"1954 Aug-Sep","pmid":"14352537","title":"[Modifications in the resistance to oxygen deficiency in the guinea pig after administration of etanautine].","journal":"Comptes rendus des seances de la Societe de biologie et de ses filiales"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Nautamine, also known as etanautine, is a small molecule drug of the etanautine class. It was originally developed by a pharmaceutical company, but its current owner is unknown. The target of etanautine is not specified, and it is not FDA-approved for any indications. As a result, there is limited information available on its commercial status, safety considerations, or pharmacokinetic properties. Further research is needed to fully understand the characteristics and potential uses of etanautine.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}